# Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

> **NCT05152459** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Tazemetostat
- **BIOLOGICAL:** Ublituximab
- **DRUG:** Umbralisib

## Key facts

- **NCT ID:** NCT05152459
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05-01
- **Primary completion:** 2024-12-15
- **Final completion:** 2024-12-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Feasibility
- **Last updated:** 2023-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152459, "Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05152459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*